Sample Applications & More

Sample Applications & More

Check out our many sample applications and summary statements. Below the list of applications, you’ll also find NIAID and NIH example forms, sharing plans, letters, emails, and more.

Table of Contents

Sample Applications

Several investigators have graciously agreed to let us post their exceptional applications online.

We are truly indebted to the investigators listed below, who have enabled us to deliver this widely anticipated resource to the research community.

We selected these applications as sound examples of good grantsmanship. That said, time has passed since these grantees applied, and so the samples may not reflect the latest application format or rules. Therefore, always follow your funding opportunity's instructions for application format. We post new samples periodically.

Note: The text of these applications is copyrighted. You may use it only for nonprofit educational purposes provided the document remains unchanged and the PI, the grantee organization, and NIAID are credited.

R01 Sample Applications and Summary Statements

PI and Grantee Institution Application Resources

Chengwen Li, Ph.D., of University of North Carolina at Chapel Hill
“Enhance AAV Liver Transduction with Capsid Immune Evasion”

Summary Statement
Full Application

Mengxi Jiang, Ph.D., of University of Alabama at Birmingham
“Intersection of polyomavirus infection and host cellular responses”

Summary Statement
Full Application

 R03 Sample Applications and Summary Statements

The small grant (R03) supports new research projects that can be carried out in a short period of time with limited resources. They are awarded for up to two years and are not renewable. R03s are not intended for new investigators.

PI and Grantee Institution Application Resources

Martin Karplus, Ph.D., of Harvard University
"Modeling atomic structure of the EmrE multidrug pump to design inhibitor peptides"

Full Application

Chad A. Rappleye, Ph.D., of Ohio State University
"Forward genetics-based discovery of Histoplasma virulence genes"

Summary Statement
Full Application

 R21 Sample Applications and Summary Statements

Please note that the R21 funds novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical research. R21s are not intended for new investigators, and there is no evidence that they provide a path to an independent research career.

PI and Grantee Institution Application Resources

Steven W. Dow, DVM, Ph.D., of Colorado State University, Fort Collins
"Mechanisms of enteric Burkholderia psuedomallei infection"

Summary Statement
Full Application

Joseph M. McCune, MD, Ph.D., of the University of California, San Francisco
"Human immune system layering and the neonatal response to vaccines"

Summary Statement
Full Application

Peter John Myler, Ph.D., and Marilyn Parsons, Ph.D., of the Seattle Biomedical Research Institute
"Ribosome profiling of Trypanosoma brucei"

Summary Statement
Full Application

Howard T. Petrie, of Scripps Florida
"Lymphoid signals for stromal growth and organization in the thymus."

Summary Statement
Full Application

Michael N. Starnbach, Ph.D., of Harvard University Medical School
"Alteration of host protein stability by Legionella"

Summary Statement
Full Application

 R21/R33 Sample Application and Summary Statement

The R21/R33 supports a two-phased award without a break in funding. It begins with the R21 phase for milestone-driven exploratory or feasibility studies with a possible transition to the R33 phase for expanded development. Transition to the second phase depends on several factors, including the achievement of negotiated milestones.

PI and Grantee Institution Application Resources

Stephen Dewhurst, Ph.D., of the University of Rochester
"The semen enhancer of HIV infection as a novel microbicide target"

Summary Statement
Full Application

 R41, R42, R43, and R44 Sample Applications

The SBIR (R43/R44) and STTR (R41/R42) programs support domestic small businesses to engage in research and development with the potential for commercialization.

PI and Grantee Institution Application Resources

Raymond Houghton, InBios International, and David AuCoin, University of Nevada School of Medicine
"Antigen Detection assay for the Diagnosis of Melioidosis" (STTR Phase II / R42)

Full Application

Mark Poritz* of BioFire Diagnostics, LLC.
"Rapid, automated, detection of viral and bacterial pathogens causing meningitis" (SBIR Phase I / R43)

Full Application

Timothy C. Fong of Cellerant Therapeutics, Inc.
"Novel indication for myeloid progenitor use: Induction of tolerance" (STTR Phase I / R41)

Full Application

Jose M. Galarza of Technovax, Inc.
"Broadly protective (universal) virus-like particle (VLP) based influenza vaccine" (SBIR Phase I / R43)

Full Application

Patricia Garrett of Immunetics, Inc.
"Rapid Test for Recent HIV Infection" (SBIR Phase II / R44)

Full Application

Michael J. Lochhead of MBio Diagnostics, Inc.
"Point-of-Care HIV Antigen/Antibody Diagnostic Device" (SBIR Phase II / R44)

Full Application

Kenneth Coleman of Arietis Corporation
"Antibiotics for Recalcitrant Infection" (SBIR Fast-Track)

Full Application

*Dr. Mark Poritz submitted the original grant application.  In the course of the first year of funding, Dr. Andrew Hemmert took on increasing responsibility for the work.  For the grant renewal, Dr. Poritz proposed that Dr. Hemmert replace him as the PI.

 F31-Diversity Sample Applications and Summary Statements

The F31-Diversity supports predoctoral students from underrepresented racial and ethnic groups, those with disabilities, and those from disadvantaged backgrounds. It also provides individualized, mentored research training from outstanding faculty sponsors.

PI and Grantee Institution Application Resources

Adjoa R. Smalls-Mantey of Columbia University Health Sciences
"Characterization of Antibody-Dependent Cellular Cytotoxicity in HIV Infection"

Summary Statement and Full Application

Juan Calix of University of Alabama at Birmingham
"The role of wcjE disruption in pneumococcal serotype 11A humoral escape"

Summary Statement and Full Application

 NIAID and NIH Sample Forms, Plans, Letters, Emails, and More

NIAID

NIH

Content last reviewed on October 27, 2016

Have Questions?

A program officer in your area of science can give you application advice, NIAID's perspective on your research, and confirmation that NIAID will accept your application.

Find contacts and instructions at When to Contact a NIAID Program Officer.